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An increasing body of evidence highlights an intriguing interaction between microRNAs
and transcriptional factors involved in determining cell fate, including the well known “ge-
nome guardian” p53. Here we show that miR-205, oncosuppressive microRNA lost in breast
cancer, is directly transactivated by oncosuppressor p53.
Moreover, evaluating miR-205 expression in a panel of cell lines belonging to the highly ag-
gressive triple negative breast cancer (TNBC) subtype, which still lacks an effective targeted
therapy and characterized by an extremely undifferentiated and mesenchymal phenotype,
we demonstrated that this microRNA is critically down-expressed compared to a normal-
like cell line. Re-expression of miR-205 where absent strongly reduces cell proliferation, cell
cycle progression and clonogenic potential in vitro, and inhibits tumor growth in vivo, and
this tumor suppressor activity is at least partially exerted through targeting of E2F1, master
regulator of cell cycle progression, and LAMC1, component of extracellular matrix involved
in cell adhesion, proliferation and migration.
Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.1. Introduction first report describing a microRNA signature unique for breastThe involvement of microRNAs in the biology of human can-
cer is supported by an increasing body of experimental evi-
dence, that has gradually switched from profiling studies to
biological demonstrations of the causal role of these small
molecules in the tumorigenic process, modulating oncogenic
or tumor suppressor pathways, and the possible implications
as biomarkers or therapeutic tools (Iorio and Croce, 2009). The3.
(C.M. Croce).
work.
Elsevier B.V. on behalf ocancer and associating microRNA expression to specific bio-
pathological features was published by our group in 2005
(Iorio et al., 2005).
Previous studies showed that miR-205 expression is signif-
icantly underexpressed in human breast cancer (Iorio et al.,
2009) (Wu et al., 2009), and able to interfere with HER receptor
family-mediated survival pathway by directly targeting HER3
receptor (Iorio et al., 2009). In addition, other studies indicatedf Federation of European Biochemical Societies.
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Mesenchymal Transition (EMT), targeting ZEB1 and ZEB2 tran-
scription factors, and that its expression is lost in mesenchy-
mal breast cancer cell lines (Gregory et al., 2008). Moreover,
miR-205 also targets VEGF-A (Wu et al., 2009) and inhibits
Src-mediated oncogenic pathways in renal cancer (Majid
et al., 2011).
In this study we aimed to identify novel potential oncosup-
pressive pathways depending on miR-205 in triple negative
breast cancer (TNBC), an extremely aggressive tumor sub-
group, negative for HER2, ER and PgR, characterized by an un-
differentiated phenotype, and still lacking a specific therapy.
Concerning miR-205 expression in different subgroups of
breast tumors, Sempere and colleagues (Sempere et al., 2007)
described miR-205 expression to be restricted to the myoepi-
thelial/basal cell compartment of normal mammary ducts
and lobules and reduced or completely eliminated in match-
ing tumor specimens, and a very recent study (Radojicic
et al., 2011) reported that miR-205 expression is significantly
underexpressed in primary TNBCs compared to the normal
counterpart.
Using as a model TNBC cell lines (MDA-MB-231 and BT-
549), we first confirmed that miR-205 exerts an oncosuppres-
sive activity, reducing cellular proliferation both in vitro and
in vivo. Our results demonstrate that miR-205 directly targets
E2F1, a transcriptional factor playing a crucial role in the reg-
ulation of cell cycle progression (Polager and Ginsberg, 2009),
and LAMC1, a component of the extracellular matrix, impli-
cated in a wide variety of biological processes including cell
adhesion, differentiation, migration and metastasis (Martin
and Timpl, 1987). Finally we analyzed the transcriptional
unit of miR-205 in order to clarify the molecular mechanisms
affecting its expression: interestingly, here we demonstrate
that tumor suppressor p53, whose mutations and loss repre-
sent one of themost common genetic changes in human neo-
plasias including breast cancer, is able to positively modulate
miR-205 expression levels in different cellular models, and
that this effect is exerted through direct binding of the tran-
scription factor on regulatory sequences upstream the micro-
RNA coding gene.2. Materials and methods
2.1. Cell culture, transfections and treatments
All the cell lines used in this work were purchased from the
American Type Culture Collection (ATCC). HEK-293, MCF7,
SAOS-2 cells were grown in Dulbecco’s modified Eagle me-
dium (DMEM), MDA-MB-231 and BT-549 cells in Roswell Park
Memorial Institute 1640 (RPMI) medium, both containing
10% heat-inactivated fetal bovine serum (FBS), 2 mM l-gluta-
mine and 100 U/mL penicillinestreptomycin. SUM-149
were cultured in DMEM-F12 containing 10% heat-inactivated
fetal bovine serum (FBS), 2 mM l-glutamine, 100 U/mL penicil-
linestreptomycin and 5ug/ml insulin. All transfections were
carried out with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions.
MCF7cells, previously transfectedwith siRNA-CTRorsiRNA-
p53 (Santa Cruz Inc., Santa Cruz, CA) were treated for 24 or 48 hwith 10 mMNutlin-3a (Cayman Chemical Company, Ann Arbor,
MI) or vehicle (DMSO), or with 10 mg/ml 5-fluorouracil (5-FU,
SigmaeAldrich, St. Louis, MO) or vehicle (DMSO).
For promoter methylation experiments, MDA-MB-231 and
BT-549 cells were treated with 10 mM 5-Aza-20-deoxycytidine
(SigmaeAldrich).
2.2. Plasmid construction
The expression plasmids for miR-205 (Vec-miR-205) and the
corresponding empty vector (miR-Vec) were kindly provided
by Dr. Reuven Agami (The Netherlands Cancer Institute,
Amsterdam, the Netherlands). The plasmid encoding
LAMC1-shRNA (sh-LAMC1), E2F1-shRNA (sh-E2F1) and the
corresponding empty vector (sh-CTR) were purchased from
Origene (Rockville, MD). For luciferase reporter experiments,
a region of 1017 bp of the E2F1 30 untranslated region (UTR)
or 244 bp of the LAMC1-30-UTR including the binding site for
miR-205 was amplified from HEK-293 cells. The PCR product
was then digestedwith XbaI and cloned into the reporter plas-
mid pGL3 control (Promega, Madison, WI) downstream of the
luciferase gene. Mutations into themiR-205 binding site of the
E2F1 or LAMC1-30UTR were introduced using Quik-Change
Site-Directed Mutagenesis kit (Agilent Technologies, Santa
Clara, CA).
Primers for plasmid construction and mutagenesis were:
E2F1 Fw: 50-TCTAGACTTGGAGGGACCAGGGTTTC-30
E2F1 Rev: 50-TCTAGAAAAGCAGGAGGGAACAGAGC-30
LAMC1 Fw: 50-TCTAGAAATCGGGAACAAAGGGTTTT-30
LAMC1 Rev: 50-TCTAGATAACTAAAAGCACTGATGGATGG-30
E2F1-Mut-A-Fw: 50-GTGTGTGCATGTACCGGGGACGCGGCGT-
GAACATACACCTCTGTC-30
E2F1-Mut-A-Rev: 50-GACAGAGGTGTATGTTCACGCCGCGTCCCCGG-
TACATGCACACAC-30
E2F1-Mut-B-Fw: 50-GTTCTTCTGCCCCATACGCGGCCGACTGA-
GGCCTGGGTGA-30
E2F1-Mut-A-Rev: 50-TCACCCAGGCCTCAGTCGGCCGCGTATGGGG-
CAGAAGAAC-30
LAMC1-Mut-Fw: 50-CTCAGTACTCTTGTTTCTCGCGGCCGAAA-
GTTTGGCTACTAACA-30
LAMC1-Mut-Rev: 50-TGTTAGTAGCCAAACTTTCGGCCGCGA-
GAAACAAGAGTACTGAG-30
Tomap themiR-205 promoter, region HPR (described in the
results section) was amplified by PCR and cloned at the NheI
and XhoI sites of the pGL3 basic vector (Promega). A region
of 2000 bp upstream miR-205 locus (spanning the p53 binding
site and named p53BR) was cloned at the NheI and XhoI sites
of the pGL3-promoter (pGL3p) vector (Promega).
HPRFw-NheI 50-GCTAGCCAGTCCCCGGCACCCCAGGCTGCTC-30
HPR Rev-XhoI 50-CTCGAGGGGTGAGCAAGAGGGACTCAGCCCA-30
P53BRFw-NheI 50-GCTAGCCGTGCATGTGCTTGGCTCTAGACCC-30
P53BRRev-XhoI 50-CTCGAGCAGAGGGTGGGGATGCATGTCAACC-30
Full-length p53 cDNA, excised by BamHI digestion of plas-
mid pC53-SN3 (Baker et al., 1990), was subcloned into plasmid
pIREShyg (Clontech, Mountain View, CA) and designated
pIRES/p53.
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quantification and semi-quantitative RT-PCR
Quantitative real-time PCR (qRT-PCR) was performed with the
TaqMan PCR Kit (Applied Biosystems, Foster City, CA) accord-
ing to manufacturer’s instructions. Normalization was
performed with RNA U44/U48 or U6 RNA. For quantification
of p53 and E2F1 mRNAs, the appropriate TaqMan probes
were purchased from Applied Biosystems.
Semi-quantitative RT-PCR was performed with the Super-
Script One-Step RT-PCR (Invitrogen) according to manufac-
turer’s instructions. Primers used formiR-205 Host Genewere:
miR-205 HG Fw 50-TGGGCTGAGTCCCTCT-30
miR-205 HG Rev 50-GAGGGACGGGTGATGGGCAGATTGG-30
Primer used for GAPDH were:
GAPDH Fw 50-CTGCACCACCAACTGCTTA-30
GAPDH Rev 50-CATGACGGCAGGTCAGGTC-30
2.4. Stable transfections and cell colony forming assay
MDA-MB-231 and BT-549 cells were plated in 100-mm
dishes and transfected with 8 mg of Vec-miR-205 or miR-
Vec as control. After 48 h, Blasticidin (InVivoGen, San Diego,
CA) was added at the final concentration of 5 mg/mL. Three
weeks after the onset of drug selection, colonies were
counted using the QuantityOne software. The mean  S.D.
of three independent experiments performed in triplicate
was reported.
2.5. Immunohistochemical analysis
Tissue Micro-Arrays (TMAs) were purchased from BioMax
(BR1503) (Biomax, Rockville, MD). In situ hybridization was
performed as previously described (Nuovo et al., 2009), using
a miR-205 probe (Exiqon, Vedbaek, Denmark). Immunohisto-
chemical analyses were performed according to standard pro-
cedures (Nuovo et al., 2009), using the anti-LAMC1 (sc-17751)
and anti-E2F1 (sc-251) antibodies (Santa Cruz Inc., Santa
Cruz, CA). Combined images were also analyzed by using the
Nuance multispectral imaging system (Caliper Life Science,
Hopkinton, MA). Correlation between miR-205 and E2F1 or
miR-205 and LAMC1 expression was evaluated by chi-square
test using Yates’ correction.
2.6. Proliferation assays
Proliferation assay was performed as previously described (Di
Leva et al., 2010).
2.7. In vivo experiments
5  106 cells (Vec-miR-205#2 or Vec-miR-205#20) mixed to
Matrigel were subcutaneously injected in SCID mice (4 mice
for each group), and tumor growth was monitored evaluating
the tumor size according to the following function: d2 x D/2
(where d is the minor diameter, whereas D is the major
diameter).2.8. Cell cycle analyses
Cells were treated with thymidine 2 mM for 16 h, released in
complete medium for 8 h and blocked with thymidine for 17
additional hours. After the second release, cells were collected
every 2 h for 8 h and then analyzed as previously described (Di
Leva et al., 2010). The data obtainedwere analyzed usingMod-
Fit software, 3.2 version (Verity Software House).2.9. Apoptosis assay
Apoptosis was quantified by using Caspase-Glo 3/7 assay
(Promega) according to the manufacturer’s instructions on
a Bio-Tek Synergy HT multi detection microplate reader. The
assay was performed three times in triplicate and the
mean þ S.D. was reported.2.10. BrDU assay
Twenty-four hours following the seeding, cells were treated
with 2 mM thymidine for 16 h, then washed twice with PBS
and cultured for 8 h in complete medium. Cells were then
treated again with 2 mM thymidine for 17 h, to synchronize
them in G1 phase of the cell cycle. Following the thymidine
double block, cells were then cultured in complete medium
containing 1mMBrdU and harvested at different time points.
Harvested cells were fixed and stained using the BrdU Flow
Kit (BD Pharmingen, San Diego, CA), according to the
manufacturer’s instructions. Stained cells were analyzed by
flow cytometry, as described above. The assay was per-
formed three times in triplicate and the mean  S.D. was
reported.2.11. Senescence assay
Senescence Associated-b-galactosidase activity was assessed
by using Senescence b-galactosidase Staining Kit (Cell Signal-
ing, Danvers, MA), following the manufacturer’s instructions.
At least 20 fields, observed by contrast phase microscopy, for
each experimental point were analyzed. Reported values are
the mean  S.D. of three independent experiments.2.12. Luciferase assays for target and promoter
identification
250 ng of pGL3 reporter vector carrying the miR-205 binding
site, 25 ng of the phRL-SV40 control vector (Promega), and
100 nMmiRNA precursors or scrambled sequencemiRNA con-
trol (Ambion Inc, Austin, TX) were cotransfected into HEK-293
cells in 24-well plates.
Tomap themiR-205promoter, 250ng of pGL3 basic reporter
vector (Promega) carrying the region HPR and 25 ng of the
phRL-SV40 control vector were cotransfected into HEK-293
cells in 24-well plates. Firefly luciferase activity wasmeasured
with a Dual Luciferase Assay Kit (Promega) 24 h after transfec-
tion and normalized with a Renilla luciferase reference plas-
mid. Reporter assays were carried out in quadruplicate and
the mean  S.D. was reported. Statistical significance was an-
alyzed by the unpaired Student t-test.
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Protein extraction andwestern blots were performed as previ-
ously described (Di Leva et al., 2010).
The antibodies used were: anti-LAMC1 (sc-17751, Santa
Cruz Inc), anti-p53 (Santa Cruz Inc, sc-126), anti-E2F1 (sc-251,
Santa Cruz Inc), anti-GAPDH (2118, Cell Signaling), B23 (sc-
53175, Santa Cruz Inc).
2.14. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were per-
formed with the ChIP assay kit (Upstate Biotechnology, Lake
Placid, NY) with minor modifications as previously described
(Di Leva et al., 2010). The primary antibody used for immuno-
precipitation was mouse monoclonal p53 (sc-126, Santa Cruz
Inc.). Primers used for PCR amplification were:
p53BS-FW 50-ACAAGCCCCAGGAAGAAAGT-30
p53BS-REV 50-TTGTTGGTCATGAGGATGGA-30
p21BS FW 50-TTGTTCAATGTATCCAAAAGAAACA-30
p21BS REV 50-TGAGATAAAGCTTCTTCCCTTAAAAA-32.15. Nuclear/cytoplasmic differential protein extraction
and electrophoretic mobility shift assay (EMSA)
Nuclear/Cytoplasmic differential protein extraction was per-
formed by using the NE-PER Nuclear and Cytoplasmic extrac-
tion kit (Pierce) according to the manufacturer’s instructions.
EMSA assays were performed by using the LightShift
Chemiluminescent EMSA kit (Thermo, Rockford, IL) according
to the manufacturer’s instructions.
The oligonucleotide sequences of the p53-responsive ele-
ment (p53RE) or its mutated form (p53RE MUT) were pur-
chased as biotinilated or non biotinilated single strands from
Operon (Huntsville, AL).
p53BSWt-Fw 50-ACTGAGCCATGGGCATGTCTGAACACAACA-30
p53BSMut-Fw50-ACTGAGCCATCCCGGCCGGCGAACACAACA-30
p53BSWT-Rev 50-TGTTGTGTTCAGACATGCCCATGGCTCAGT-30
p53BSMut-Rev50-TGTTGTGTTCGCCGGCCGGGATGGCTCAGT-30
2.16. Statistical analysis
Student’s t-test was used to determine statistical significance.
All error bars represent the standard deviation (S.D.) of the
mean or the standard error (S.E.). Statistical significance for
all the tests was assessed by calculating the p-value.3. Results
3.1. miR-205 is downregulated in TNBC and inhibits
in vitro and in vivo growth of MDA-MB-231 cells
We first evaluated miR-205 expression in a panel of 10 Triple
Negative and 1 Normal-like breast cancer cell lines, finding
a significant ( p < 0.05) downregulation in TN cell lines
(Supplementary Figure 1) compared to the Normal-like one.As a model for functional studies, we chose MDA-MB-231
and BT-549 cell lines.
We first performed a colony forming assay in MDA-MB-231
and BT-549 cells transfected with a plasmid encodingmiR-205
(Vec-miR-205) or the corresponding empty vector (miR-Vec).
As shown in Figure 1A, the ability to form colonies was se-
verely impaired inmiR-205 overexpressing cells (colony count
in Figure 1B). miR-205 overexpression in Vec-miR-205 cells
compared to empty vector transfected cells was confirmed
by qRT-PCR (Supplementary Figure 2AeB).
Subsequently, two stable clones of MDA-MB-231 (Vec-miR-
205#2 and Vec-miR-205#20) overexpressing miR-205
(Figure 1C) in comparison to a single miR-Vec clone (miR-
Vec#1) were selected out from the corresponding bulk popula-
tions. Growth kinetics analysis by SRB assay reveals that
growth of both miR-205-expressing clones was slower than
the control vector clone (Figure 1D).
To confirm that the in vitro inhibitory effects of miR-205 on
MDA-MB-231 cells could also reflect an impairment of their
in vivo tumorigenicity, we developed xenograft models and re-
sults indicate that growth of tumors deriving from Vec-miR-
205#2 and Vec-miR-205#20 clones was significantly inhibited
in comparison with tumors originating from control miR-
Vec#1 clone: indeed, after 21 days, mice injected with the
two miR-205 overexpressing clones developed a tumor mass
of 144 and 326 mm3 respectively (growth inhibition of 74%
and 40% respectively) (Figure 1E), whereas in control mice
the tumor reached a volume of 546 mm3. miR-205 expression
was conserved in xenograft tumors, as validated by qRT-PCR
(Figure 1F). We can thus affirm that miR-205 inhibits in vivo
growth of MDA-MB-231 cells.
3.2. miR-205 affects cell cycle progression and cellular
senescence by targeting E2F1
To shed more light on the mechanism of miR-205-mediated
inhibition of MDA-MB-231 and BT-549 cell growth, asynchro-
nously growing miR-Vec#1, Vec-miR-205#2 and #20 clones
were analyzed by flow cytometry. Figure 2AeB shows that
miR-Vec#1 displayed a percentage of cells in G1 phase of the
cell cycle significantly lower compared to Vec-miR-205#2 and
#20 (55.45% vs 64.64% and 65.47%, respectively). Similar results
were obtained in BT-549 cells (Supplementary Figure 3AeB).
Moreover, results shown inFigure2Aand inSupplementary
Figure3Asuggest that reducedgrowthofmiR-205overexpress-
ing clones is not due to apoptosis induction, since no sub-G1
population was observed in comparison to miR-Vec#1 clone.
However, to further investigate this issue, we evaluated Cas-
pase 3/7 activation following transient transfection of miR-
205 in MDA-MB-231 cells, and no significant apoptosis induc-
tion was observed at 72 h or 96 h (Supplementary
Figure 4AeB), indicating that the reduced growth rate observed
in miR-205 overexpressing clones could not be due to an in-
creased apoptosis.
To better analyze the G1/S transition in these clones, miR-
Vec#1 and Vec-miR-205#2 and #20 cells were synchronized in
G1 by a thymidine double block, released in completemedium
and collected after 2, 4, 6, 8 h, and cell cycle distribution deter-
mined by FACS analysis. As shown in Supplementary
Figure 5AeB, the percentage of the G1 resting cells in the
Figure 1 e miR-205 inhibits cell proliferation in vitro and in vivo in MDA-MB-231 cells. (A) Inhibition of colonies formation obtained
transfecting MDA-MB-231 or BT-549 cells with a vector encoding miR-205 (Vec-miR-205) compared to the corresponding empty vector
(miR-Vec). (B) Quantitative analysis of the experiment shown in A, indicating colony formation inhibition ( p< 0.01) from three independent
experiments. Error bars represent the standard deviation (S.D.) calculated on 3 replicates. (C) Selection of two clones from the MDA-MB-231
VEC-miR-205 bulk population. miR-205 overexpression in Vec-miR-205#2 and #20 clones was evaluated by qRT-PCR. Error bars represent S.D.
calculated on 3 replicates. (D) SRB assay highlights a reduced growth kinetic in miR-205 overexpressing clones in comparison with control cells
( p< 0.001). Bars indicate S.D. calculated on 6 different replicates. (E) In vivo growth kinetics of stable clones subcutaneously injected in SCID
mice. Bars indicate standard error (SE) calculated on two different experiments performed with four mice for each group (*p< 0.05; **p< 0.01;
***p< 0.001). (F) qRT-PCR analysis verifies miR-205 expression in xenograft tumors. Bars indicate S.D. calculated on 3 different replicates.
M O L E C U L A R O N C O L O G Y 6 ( 2 0 1 2 ) 4 5 8e4 7 2462miR-Vec#1 clone was lower compared to Vec-miR-205#2 and
#20 at 4 h (29.95% vs 43.65% and 32.35%, respectively) and
6 h (25.2% vs 36.61% and 32.48%, respectively) from the re-
lease. In addition, to quantify the G1 checkpoint activation,
we performed BrdU incorporation assays in these clones. Cellswere synchronized in G1 phase by thymidine double block,
then released in complete medium containing 1 mM BrdU.
Cells were harvested at different time points and stained us-
ing an anti-BrdU antibody. BrdU incorporation was then eval-
uated by flow cytometry analysis. As shown in Figure 2C, BrdU
Figure 2 e miR-205 effects on cell cycle progression and cellular senescence. (A) Cell cycle analysis of asynchronously growing miR-Vec#1,
Vec-miR-205-#2 and #20 clones. Cells were harvested after 72 h following the seeding, fixed, stained with propidium iodide and analyzed by flow
cytometry. The data obtained were analyzed using ModFit software. Cells in G1 and in G2 phase of cell cycle are reported in red, cells in S phase
are indicated with white and blue bars. Flow cytometry plots shown are representative of three independent experiments. (B) Graphic
representation of relative percentage of cells in G1, S, or G2 phase relative to the experiment shown in A. Percentages of cells in each compartment
are means of three independent experiments. (C) miR-Vec#1, Vec-miR-205-#2 and #20 clones were synchronized in the G1 phase of the cell cycle
by thymidine double block, and then cultured in BrdU conditioned medium, harvested at different time points and stained using an anti-BrdU
antibody. The percentage of BrdU positive cells for each time point was analyzed by flow cytometry analysis. Values are the mean ± S.D. of three
independent experiments. (D) Total extracts from miR-Vec#1, Vec-miR-205#2 and #20 clones were analyzed by western blot for E2F1 detection
(upper panel). Densitometric analysis of E2F1 bands is reported in the lower panel. (EeF) SA-b-gal-staining was performed on miR-Vec#1,
Vec-miR-205-#2 and #20 clones and light microscope cell images were acquired. The percentage of SA-b-gal positive cells is reported (E). Values
are the mean ± S.D. of three independent experiments. A representative image of each SA-b-gal stained clone is reported. Arrows highlight
senescent-like cellular morphology and SA-b-gal-staining in 205#2 and 205#20 clones (F).
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pared to Vec-miR-205#2 and #20 ( p < 0.001 at all indicated
time points).
Considering previous data reporting that miR-205 down-
regulates E2F1, a factor critically involved in cell cycle progres-
sion from G1 to S phase (Polager and Ginsberg, 2009), in pros-
tate (Gandellini et al., 2009) and melanoma (Dar et al., 2011),
we evaluated by western blot analysis protein extracts from
asynchronously growing MDA-MB-231 and BT-549 cells,
showing reduced E2F1 protein levels in miR-205 overexpress-
ing clones (Figure 2D and Supplementary Figure 5C).Interestingly, we also observed a significant morphologic
change in miR-205 overexpressing clones, which displayed
an enlarged cellular size resembling a senescence-like pheno-
type. Because of the well known association between reduced
E2F1 levels and the induction of cellular senescence (Maehara
et al., 2005), we investigated whether miR-205 overexpression
could result in senescence induction. As shown in
Figure 2EeF, the percentage of senescence associated-b-galac-
tosidase (SA-b-gal) was significantly higher in Vec-miR-205#2
clone compared tomiR-Vec#1. Moreover, Figure 2F also shows
the enlarged phenotype observed in this clone.
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205 overexpressing clones, we investigated whether this
transcription factor is directly targeted by miR-205 in our
models. We first observed that overexpression of miR-205
for 72 or 96 h (verified by qRT-PCR, Figure 3A, upper panel)
strikingly decreased E2F1 mRNA (Figure 3A middle panel)
and protein expression (Figure 3A, lower panel). Similar
results were obtained in BT-549 cells (Supplementary
Figure 6A). Conversely, inhibition of miR-205 expression
by transfecting an anti-miR-205 in SUM-149 cells
(displaying relatively higher levels of miR-205 compared
to other TN cell lines) resulted in an increase of E2F1Figure 3 e miR-205 directly targets E2F1. (A) Transfection ofMDA-MB-231
collection ofRNAandproteins after 72h and 96h.miR-205 expressionwas eva
and protein levels were quantified by western blot. (B) Schematic representatio
and poorly conserved-B) on the wild-type E2F1-30UTR and the mutated cont
E2F1-30UTR-mut-B and E2F1-30UTR double mutant (DM) plasmids was de
representative of four independent experiments. Bars indicate S.D. calculated
the inhibition of colony formation obtained by transfecting MDA-MB-231 ce
with the corresponding empty vector (sh-CTR) and (E) Down-modulation ofexpression, both at protein and mRNA level
(Supplementary Figure 6B).
miR-205 was predicted by TargetScan software to bind the
E2F1 30UTR at two different sites, A (highly conserved) and B
(poorly conserved) (Figure 3B). 1017 bp of E2F1 30UTR were
inserted in a reporter vector that was cotransfected in HEK-
293 cells with miR-205 precursor molecule or a scrambled oli-
gonucleotide as control, and a luciferase assay was then per-
formed. Overexpression of miR-205 significantly inhibited
E2F1 30UTR luciferase activity relative to the control (w60% re-
duction, p < 0.01), whereas E2F1 30UTR containing mutations
at site A or B or both escaped this inhibition (Figure 3C).cells with 100 nmol/L preemiR-205 or a scrambled oligonucleotide and
luatedby real-timePCR.E2F1mRNA levels was evaluated byqRT-PCR
n of the interaction between miR-205 and the binding site (conserved-A
rol. (C) Luciferase activity for E2F1-30UTR-wt, E2F1-30UTR-mut-A,
termined 24 h after transfection of HEK-293 cells. The results are
on 3 different replicates ( p< 0.01). (D) Phenocopy experiment showing
lls with a vector encoding a shRNA silencing E2F1 (sh-E2F1) compared
E2F1 protein (evaluated by western blot) 96 h after transfection.
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205 were mediated, at least in part, by regulation of E2F1, we
performed phenocopy experiments by directly silencing E2F1
by shRNA approach. We evaluated in vitro effects on cell
growth by performing a colony forming assay on MDA-MB-
231 cells transfected with a plasmid encoding an shRNA spe-
cifically directed against E2F1 (sh-E2F1) or the corresponding
empty vector (sh-CTR). As shown in Figure 3D, efficient knock
down of E2F1 (evaluated by Western Blot, lower panel) de-
creased the ability to form colonies (30% inhibition) (upper
panel). In addition, silencing of E2F1 results in a slower cell cy-
cle progression from G1 to G2 phase: sh-CTR bulk population
displayed a percentage of cells in G1 phase significantly lower
compared to sh-E2F1 one (33.84% vs 42.72%) (Supplementary
Figure 6C).
In order to investigate the potential inverse correlation be-
tweenmiR-205 and E2F1, we first looked at E2F1 expression in
a previously published gene profiling (Farazi et al., 2011), and
we found it overexpressed in tumor samples versus normal
breast ( p ¼ 0.014) (data not shown). Moreover E2F1, already
reported as upregulated in basal tumors (Docquier et al.,
2010), was confirmed to be overexpressed in TNBC vs normal
tissue in the same dataset we analyzed (Farazi et al., 2011)
( p ¼ 0.0167) (data not shown).
To further assess this potential inverse correlation be-
tween miR-205 and E2F1 expression in human breast cancer,
we analyzed a tissue micro-array (TMA), including 117 breast
cancer cases, by immunohistochemistry (IHC) and in situ hy-
bridization for both E2F1 andmiR-205, respectively. Each sam-
ple was scored for the expression of both miR-205 and E2F1,
independently. As shown in Supplementary Figure 7A and B,
E2F1 was abundantly expressed in the analyzed breast cancer
samples (67% of cases), whereasmiR-205 was observed in 43%
of cases. Even though we did not observe a significant
( p ¼ 0.843, Yates’ p-value) inverse correlation between miR-
205 and E2F1 expression, interestingly Nuance analysis
revealed that in most of the double positive (miR-205 and
E2F1) samples, the co-expression was not observed in the
same cells from each sample (Supplementary Figure 7C).
Thus, a further statistical analysis, performed excluding dou-
ble positive samples in which E2F1 and miR-205 were not
expressed by the same cells, indicated a significant inverse
correlation ( p ¼ 0.006, Yates’ p-value) between their expres-
sion levels. Hence, these results further support that E2F1 is
a target of miR-205, also in breast cancer tissues.
3.3. miR-205 directly targets LAMC1
To better explain the biological effectsmediated bymiR-205 in
our experimental model, we investigated new additional tar-
gets. Among themRNAspotentially targeted bymiR-205, iden-
tified using the miRGen database (Megraw et al., 2007), we
selected a component of the extracellular matrix named
LAMC1. This protein has been implicated in a wide variety of
biological processes including cell adhesion, differentiation,
proliferation, migration, signaling, neurite outgrowth andme-
tastasis, and it is altered in human hepatocellular carcinoma
(Lietard et al., 1997), breast cancer (Valladares et al., 2006)
and glioblastoma, where it is targeted by miR-124a (Fowler
et al., 2011).We first observed the down-modulation of LAMC1 protein
levels (but not in mRNA level, data not shown) in MDA-MB-
231 breast cancer cells transfected with miR-205 precursor
molecule (Figure 4A, upper panel) in comparisonwith a scram-
bled oligonucleotide (Figure 4A, lower panel). Similar results
were obtained in BT-549 cells (Supplementary Figure 8A). Con-
versely, transfection with the anti-miR-205 in SUM-149 cells
increased LAMC1 protein expression (Supplementary
Figure 8B). A luciferase reporter assay was then performed
to demonstrate a direct regulation: the reporter vector con-
taining 244 bp of LAMC1-30UTR, including the binding site
for miR-205 (Figure 4B, upper panel), was cotransfected in
HEK-293 cellswithmiR-205 precursormolecule or a scrambled
oligonucleotide as a control, and the luciferase activity was
significantly decreased (w30% reduction, p < 0.05) after miR-
205 overexpression (Figure 4B, lower panel). Moreover, the
mutation of the miR-205 binding site in LAMC1 30UTR pre-
vented the downregulation of luciferase expression.
To evaluate whether the biological effects exerted by miR-
205 were partially mediated also by regulation of LAMC1, we
performedphenocopyexperiments. To this aim,weperformed
a colony forming assay on MDA-MB-231 cells transfected with
a plasmid encoding an shRNA specifically directed against
LAMC1 (sh-LAMC1) or the corresponding empty vector (sh-
CTR) (Figure 4D). As shown in Figure 4C, direct knock down of
LAMC1 consistently decreased the ability to form colonies
(35% reduction compared to the sh-CTR transfected cells).
To verify the inverse correlation between miR-205 and
LAMC1 also in breast cancer samples, we performed IHC and
in situ hybridization for LAMC1 and miR-205, respectively, us-
ing a TMA including 111 breast cancer samples.
Supplementary Figure 9AeB shows the high LAMC1 levels in
the analyzed samples (45%). As well as for E2F1, we did not ob-
serve a significant correlation ( p ¼ 0.0681, Yates’ p-value) be-
tween LAMC1 and miR-205 expressions. However, by
correcting the statistical analysis excluding double positive
cases in which miR-205 and LAMC1 were not expressed by
the same cells (using the Nuance system, Supplementary
Fig. 9C), we observed a significant inverse correlation between
miR-205 and LAMC1 expression. These data further indicate
that miR-205 targets LAMC1 also in breast cancer tissues.
3.4. Transcriptional regulation of miR-205
HumanmiR-205 (hsa-miR-205) is located within the hypothet-
ical gene LOC642587 at chromosome 1q32.2 region, where
preemiR-205 overlaps the junction between the third intron
and the fourth exon of LOC642587. It has not been demon-
strated yet whether miR-205 has its own promoter or is co-
regulated by LOC642587, and mechanisms regulating the ex-
pression of miR-205 and the consequent biological reasons re-
sponsible for the downregulation of this microRNA in breast
cancer have not been identified yet. The only evidence
reported to date is the two fold increase in miR-205 levels in
MCF7 treated with demethylating agent 5-aza-20-deoxycyti-
dine (Wu and Mo, 2009), consistent with the presence of
a CpG island about 300 bp before the first exon of the host
gene (Bhatnagar et al., 2010). However, a deeper investigation
of additional possible mechanisms regulating miR-205 ex-
pression has not been performed to date.
Figure 4 e miR-205 directly regulates LAMC1. (A) Transfection of MDA-MB-231 cells with 100 nmol/L preemiR-205 or a scrambled
oligonucleotide and collection of RNA and proteins after 72 h and 96 h. miR-205 expression was evaluated by real-time PCR (upper panel).
LAMC1, and Vinculin as loading control, were quantified by western blot (middle panel). Densitometric analysis of LAMC1 bands is reported in
the lower panel. (B) Schematic representation of the interaction between miR-205 and the binding site on the wild-type LAMC1-30UTR and the
mutated control. Luciferase activities (lower panel) for LAMC1-30UTR-wt and LAMC1-30UTR-mut plasmids were determined 24 h after
transfection of HEK-293 cells. The results are representative of 4 independent experiments. Bars indicate S.D. calculated on 3 different replicates
( p< 0.05). (C) Phenocopy experiment showing the inhibition of colony formation obtained by transfecting MDA-MB-231 cells with a vector
encoding a shRNA silencing LAMC1 (sh-LAMC1) compared with the corresponding empty vector (sh-CTR) and (D) Down-modulation of
LAMC1 protein (evaluated by western blot) 48 h after transfection.
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identified transcription starting site of miR-205 (Bhatnagar
et al., 2010), a 7333 bp sequence upstream miR-205 coding re-
gion has been analyzed using a bioinformatic program (Pro-
moter 2) for the presence of putative promoter regions. We
focused on the region immediately upstream the first exon
of LOC642587 (scored as “highly likely predicted”, HPR). To de-
termine whether this region (Figure 5A) could represent the
miR-205 transcriptional promoter, we constructed reporter
plasmids by inserting fragments of 2 kb spanning this region
into the promoterless vector pGL3 basic, upstream the lucifer-
ase gene.HEK-293 cells were transfected with the obtained vectors
and luciferase activity quantified 24 h after transfection. Cells
transfected with the vector containing the HRP region dis-
played a luciferase activity higher (fold change is about 7 folds,
p < 0.001) than cells transfected with the empty vector, sug-
gesting that this region exerts a promoter activity on miR-
205 expression (Figure 5B).
Based on the previous reported data suggesting the poten-
tial role of methylation on the regulation miR-205 levels (Wu
and Mo, 2009), we analyzed the effect of the demethylating
agent 5-Aza-20-deoxycytidine (5-Aza-dC) on miR-205 expres-
sion in two TN cell lines (MDA-MB-231 and BT-549). Cells
Figure 5 e Identification of miR-205 transcriptional region (A) Schematic representation of the genomic miR-205 locus: miR-205 is located at
human chromosome 1q32.2 locus and its precursor lies between the third intron and the fourth exon of the hypothetical gene named LOC642587.
Bar referred as HPR indicates the genomic region analyzed (highly predicted as potential promoters by promoter 2.1 software). (B) Promoter
activity of region HPR was measured by luciferase assay after 24 h of transfection of HEK-293 cells with pgl3 basic vector carrying region HPR.
Values are the mean ± S.D. of three independent experiments ( p< 0.001). (CeD) treatment of MDA-MB-231 (C) and BT-549 (D) Cells with
10 mM 5-Aza-dC and collection of RNA at indicated time points (48e120 h). miR-205 expression was evaluated by qRT-PCR. Results are the
mean of 3 independent experiments. Bars represent S.D. calculated on 3 replicates (*p< 0.05; **p< 0.01; ***p< 0.001).
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time points (48e120 h). As shown in Figure 5CeD, 5-Aza-dC
treatment significantly increased miR-205 expression, com-
pared to untreated controls, at different time points in both
cellular systems.
3.5. P53 enhances miR-205 expression
With the aim to further investigate the mechanisms regulat-
ing miR-205 expression, we used UCSC Genome Browser to
analyze the presence of potential binding sites for transcrip-
tion factors, and we found a p53 binding site (p53BS) approxi-
matively 1 kb upstream the preemiR-205 genomic sequence.
In order to investigate p53 effect on miR-205 expression, we
first transfected HEK-293 with different amounts of a p53-
encoding vector or with the corresponding empty vector. Re-
sults confirmed efficient overexpression of p53 in a dose de-
pendent manner (Figure 6A upper and lower panel
respectively) and showed an upregulation of miR-205 only in
presence of the higher dose of p53 (Figure 6 middle panel), in-
dicating that there is probably a p53-threshold level that has
to be overcome in order to activate miR-205 expression. To
further confirm this result, we transfected the same cell line
(HEK-293) with a p53-specific siRNA (or a corresponding con-
trol siRNA), thus obtaining a strong inhibition of endogenous
p53-expression (Figure 6B upper and lower panel). As shown
in Figure 6B (middle panel), silencing of p53 led to a drasticsuppression of miR-205 expression. To determine whether
miR-205 expression could be restored in a breast cancer cell
line carrying high levels of a mutated form of p53 and that
does not express miR-205, we next transfected MDA-MB-231
cells with a p53-encoding vector (or the corresponding empty
vector). P53 levels were analyzed after 48 h of transfection and
the expression of p21-encoding CDKN1A, a p53 target gene,
was also assessed to verify p53 functionality (Figure 6C, lower
panel). As reported in Figure 6C (upper panel), reintroduction
of wt p53 in this cell line is able to double miR-205 expression
( p < 0.01), indicating that the absence of a functional p53 pro-
tein in this cell line could at least partially explain the low
levels of miR-205.
To confirm the responsiveness of miR-205 to p53, a cell line
carrying a wt p53, MCF7 was treated with Nutlin-3a, a small
molecule that antagonizes the p53 inhibitor MDM2, or vehicle
(DMSO), followed by qRT-PCR (Figure 6D upper panel) to mon-
itor miRNA levels upon p53 accumulation (Figure 6D lower
panel). Induction of miR-205 transcription was detected after
24 and 48 h of Nutlin-3a treatment in MCF7 cells. MCF7 cells
were also treated with the chemotherapy agent 5-FU (5-
fluorouracil), able to mediate p53 activation (Figure 6E lower
panel) for 24 or 48 h. As reported in Figure 6E (upper panel),
this DNA-damaging agent is able to induce miR-205 expres-
sion in a wt p53 breast cancer cell line ( p < 0.01). In order to
verify that the effects of Nutlin and 5-FU are indeed p53-
dependent, drug treatment was also performed after
Figure 6 e P53 activates miR-205 expression. (A) Transfection of wt p53 in HEK-293 cells induces miR-205 upregulation in a dose dependent
manner. P53 levels after transfection were evaluated by qRT-PCR and by western Blot. miR-205 levels were measured by qRT-PCR. (B) p53
silencing in HEK-293 cells (verified by both quantitative qRT-PCR and western blot) significantly ( p< 0.001) reduces endogenous miR-205
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Figure 6DeE, the induction of miR-205 by those agents was
abolished when p53 is knocked-down. Expression of miR-205
following Nutlin-3a treatment was in line with miR-205 host
gene modulation (evaluated by sqRT-PCR, Figure 6F), suggest-
ing a possible co-transcription of miR-205 and its host gene.
In addition, to determine if the transcriptional regulation
exerted by p53 and by the 5-AZA-dC demethylating agent on
miR-205 could be additive, MCF7 cells were treated with
Nutlin-3a and 5-AZA-dC alone or combined, and miR-205 ex-
pression was then evaluated. Supplementary Figure 10A
shows that, in the presence of both drugs, miR-205 expression
displayed an increase that was higher in comparison with the
single Nutlin-3a or 5-AZA-dC treatment. Notably, 5-AZA-dC
treatment was also able to enhance endogenous p53 levels
(Supplementary Figure 10B), as previously reported (Zhu
et al., 2004).
3.6. P53 binds to and positively regulates the miR-205
upstream region
In order to clarify the p53-dependent transcription-enhancing
activity of the predicted p53 binding sequence, we performed
a luciferase reporter assay, using a pGL3-promoter reporter
construct containing 2000 bp sequence named p53 binding re-
gion (p53BR). Saos-2 cells (p53-deficient human osteosarcoma
cells) were transfected with the reporter vector (named
pGL3p þ p53BR) in presence of two different doses of a p53-
encoding vector or the corresponding empty vector
(Figure 7A, lower panel). The region analyzed yielded a robust
p53-dependent transcriptional activity (Figure 7A, upper
panel).
Indeed, to demonstrate the binding of p53 to the predicted
consensus sequence, we performed a Chromatin Immunopre-
cipitation Assay (ChIP). MCF7 cells were treated for 36 h with
Nutlin-3a (Supplementary Figure 10C). As reported in
Figure 7B, p53 binding to his predicted consensus sequence
occurred in untreated MCF7 cells and became stronger after
p53 activation uponNutlin-3a treatment. As a positive control,
we used the p53 consensus site on the CDKN1A promoter.
In addition, we conducted an Electrophoretic Mobility Shift
Assay (EMSA). Two different doses of p53 recombinant protein
(rp53) were incubated with a double stranded biotin-labeled
primer of 30 nucleotides (p53-responsive element, p53RE)
encompassing the p53BS. The p53 recombinant protein was
also incubated with the biotin-labeled p53RE in the presence
of a 200 molar excess of unlabeled p53RE. Finally, we incu-
bated the p53 recombinant protein with a mutated biotin-
labeled p53RE. As shown in Figure 7C, the p53 recombinant
protein was able to bind and shift the biotin-labeled p53RE,
and this binding was impaired by the molar excess of unla-
beled p53RE. No binding and shift was observedwhen themu-
tant p53RE was incubated with the p53 recombinant protein.level, as indicated by qRT-PCR experiment. (C) Transfection of wt p53 in
205 levels as measured by qRT-PCR ( p< 0.001). (DeE) MCF7 cells were
after transfection with Nutlin-3a (D) and 5-FU (E) for 24 or 48 h. Inductio
p53 is silenced. Western blot analysis was performed for p53 detection. (F) S
Nutlin-3a or 5-FU treatment in MCF7 cells. GAPDH expression was alsoTo demonstrate that also the endogenous p53 protein was
able to specifically interact with the biotin-labeled p53RE, we
incubated this double stranded oligonucleotide with a nuclear
protein extract fromMCF7 cells, treated with DMSO or with 10
uM Nutlin-3a (Supplementary Figure 10D). As shown in
Figure 7D, a band corresponding to the complex p53/p53RE
was observed only following Nutlin-3a treatment. Moreover,
we found the complex only in the presence of thewild-type bi-
otin-labeled p53RE, and not in the presence of the mutated
p53RE and the formation of this complex was affected by the
presence of a 200 molar excess of the unlabeled p53RE. We
also pre-incubated the nuclear protein extract with an anti-
p53 antibody, in order to obtain the formation of a p53/
p53RE/anti-p53 antibody complex (super-shift) but, likely be-
cause of the presence of a high background, we were not
able to detect a super-shifted band.
Taken together, these data demonstrate that p53 is able to
directly bind the miR-205 upstream region, driving the upre-
gulation of miR-205 expression.4. Discussion
The decision to shedmore light on the role ofmiR-205 in TNBC
is supported by the evidence that this is a very aggressive sub-
group of breast carcinomas still lacking an effective targeted
therapy, wheremiR-205 is one of themost significantly under-
expressed microRNAs (Radojicic et al., 2011) and where its
functional role and regulation have not been clearly eluci-
dated yet.
To this aim, we first analyzed a wide panel of triple nega-
tive breast cancer cell lines, observing that this microRNA is
expressed at significantly lower levels compared to a Nor-
mal-like breast cell line. Interestingly, in a very recent paper
(Prat and Perou, 2011), the cell lines we analyzed were classi-
fied as belonging to a very undifferentiated subgroup, named
claudin-low, associated to low or absent expression of adhe-
sion molecules, luminal differentiation markers, high enrich-
ment for epithelial-to-mesenchymal transition markers,
immune response genes and cancer stem cell-like features.
Notably, the only cell line that displays a higher miR-205 ex-
pression, SUM-149, does not belong to the claudin-low sub-
group, further supporting the idea that miR-205 loss could
be considered a valid marker of an undifferentiated, mesen-
chymal and aggressive phenotype.
Choosing the TNBC cell lines MDA-MB-231 and BT-549 as
cellular models, in this study we show that reintroduction of
miR-205 not only leads to a dramatic reduction of both prolif-
eration, cell cycle progression and clonogenic potential
in vitro, but it also significantly inhibits the in vivo tumor
growth in xenograft models.
Concerning the identification of newmiR-205 target genes,
we demonstrated that this microRNA directly targets LAMC1,MDA-MB-231 cells (carrying a mutated form of p53) enhances miR-
transfected with 100 nM siRNA-CTR or siRNA-p53 and treated 24 h
n of miR-205 (measured by qRT-PCR, p< 0.01) is abrogated when
emi-quantitative RT-PCR for the miR-205 host gene expression after
quantified as control.
Figure 7 e P53 directly binds a responsive element on miR-205 regulatory sequences. (A) Luciferase assay of region containing p53 binding site
(p53BR) in SAOS-2 cells (p53 null) after transfection of two different doses of p53. P53 levels after transfection were evaluated by western blot. (B)
Binding of p53 to miR-205 regulatory sequences. Cross-linked chromatin was prepared from MCF7 cells (p53 wt) treated or not with 10uM
Nutlin-3 for 24 h and subjected to ChIP assay. Binding of p53 to p21 promoter was used as control of p53 activation after Nutlin-3 treatment. (C)
EMSA showing the DNA binding activity of p53 on the miR-205 regulatory sequences. One or two hundred ng or of recombinant wild-type p53
(rp53) were added to the reaction (except lane 1 and lane 6) in presence of wild-type oligonucleotide encompassing the p53-responsive element
(p53RE*) (lane 1,2,3,4,5) or mutated oligonucleotides (p53RE MUT*) (lane 6,7,8). A 200-fold excess of wild-type oligonucleotide, encompassing
the p53-responsive element (wt) (lane 4 and 5), was used as a control of the p53-specific binding. (D) EMSA showing the increased binding of p53
on miR-205 regulatory sequences after Nutlin-3a treatment in MCF7 cells. Fifteen mg of nuclear lysate from non-treated (MCF7DDMSO) and
treated cells (MCF7DNut3) were added to the reaction in presence of wild-type oligonucleotide encompassing the p53-responsive element
(p53RE*) (lane 1,2,3,4,7,8,9) or mutated oligonucleotides (p53RE MUT*) (lane 5,6,10). A 200-fold excess of wild-type oligonucleotide
encompassing the p53-responsive element (wt) (lane 3 and 8), and anti-p53 antibody (200 ng) were added to the reaction.
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ple biological activities including promotion of cell adhesion,
proliferation, migration, differentiation and enhancement of
the metastatic phenotype of tumor cells. Phenocopy experi-
ments demonstrated that LAMC1 silencing is, at least in
part, responsible of the growth inhibition mediated by
miR-205.In addition, we also demonstrated that miR-205 directly
targets the transcription factor E2F1, master regulator of the
G1/S transition, at bothmRNA and protein levels. Reduced ex-
pression of this protein in MDA-MB-231 stable clones overex-
pressing miR-205 results in a slower cell cycle progression.
Moreover, miR-205 overexpression resulted in increased in-
duction of cellular senescence, a process which is negatively
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this case phenocopy experiments confirmed that E2F1 silenc-
ing could be responsible of the impaired cell cycle progression
observed in miR-205 overexpressing cells. These findings fur-
ther suggest that miR-205 is able to influence cell cycle pro-
gression and cell fate, through the targeting of E2F1.
Subsequently, since the mechanisms responsible for miR-
205 downregulation in breast cancer have not been elucidated
yet, we defined the promoter region of this microRNA and
searched for conserved transcription factor binding sites.
We first showed that miR-205 expression could be modu-
lated by the demethylating agent 5-AZA-dC, possibly through
miR-205 promoter demethylation or modulation of transcrip-
tional factor involved in its regulation.
Interestingly, we also demonstrated that the tumor sup-
pressor p53 is able to induce miR-205 expression in different
cellular models, and that this effect is mediated by its direct
binding on a responsive element located upstream this
microRNA.
Considering the high frequency of TP53mutations in basal-
like breast cancer (44e82%) (Sorlie et al., 2001), the transcrip-
tional induction of miR-205 by p53 may have important impli-
cations. First, the reduced expression or the occurrence of
inactivating mutations of TP53 or the presence of a wt but
non active p53 might justify the reduced levels or the com-
pletely loss (as in the case of TNBC) ofmiR-205 in breast cancer.
Moreover, the direct targeting of E2F1 mediated by miR-205,
likely to be responsible of the cell cycle arrest observed in our
experimental models, might be a new alternative regulatory
mechanism used by p53 to influence the cell fate to an anti-
proliferative choice. Indeed, it is widely demonstrated that
p53 activation blocks the release of E2F1 from its inhibitor
pRB, through the transcriptional activation of p21 (waf-1/cip-
1), which in turn negatively regulates several complexes of
cyclin/cyclindependent kinases (cdks) involved in thenegative
regulation of pRB and in the cell cycle progression from the G1
to the S-phase. Our data suggest thatmiR-205might represent
a novel pRB-independent mediator of the regulation of E2F1,
initiated by p53 in order to prevent cell cycle progression.
In conclusion, we demonstrated that miR-205 is a novel
transcriptional target of p53, and that it exerts a role as onco-
suppressor in triple negative breast cancer, and in particular
in a model representative of the most undifferentiated and
mesenchymal subgroup, through the regulation, at least in
part, of the two newly identified target genes, E2F1 and
LAMC1, thus resulting in reduced cellular proliferation, both
in vitro and in vivo.Conflict of interest
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